Nanoveu (ASX: NVU) has confirmed the first shipment of its antiviral protection product into major international markets.
The stock has been well supported since it confirmed it will meet its guidance of first revenues in early Q3 2020 after filling its first sales orders for its products.
The company’s products have been shipped to AIBI Pte Ltd, a Singapore-based fitness equipment and wellness provider to the Asia-Pacific region, which is a distributor of Nanoveu’s antiviral products in Singapore.
Nanoveu has also filled first orders from customers in other key international markets including United States of America, United Kingdom and Australia.
The distribution partners are anticipated to use the antiviral film for a number of broad applications, including protection for benchtops, computer screens and touchscreen surfaces.
For example, Keywest Technology a US-based B2B supplier has purchased Nanoveu’s antiviral product and intends to apply the film on a number of shopping centre digital kiosks.
It is exceptionally exciting to see the first shipment of our product into major international markets. We are continuing to build a global distribution network for our technology,” Nanoveu Executive Chairman and CEO Alfred Chong said.
“Nanoveu continues to expedite its mobile phone protection product but is also taking advantage of strong take-up of commercial-sized sheets of anti-viral film which our distributors are looking to use for many expanding applications.”
Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses. The technology has been proven to eliminate 99.99% of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes.
The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A592.